We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 994

Undue hardship in M.H. V. College of Nurses of Ontario: setting limits on the duty to accommodate

  • WeirFoulds LLP
  • -
  • Canada
  • -
  • December 5 2014

Regulatory colleges must review accommodation requests from individuals with disabilities within the context of their public protection mandate. The

Punitive damages not available under section 8 of the PM (NOC) Regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

The Supreme Court of Canada has refused Teva’s application for leave to appeal the decision of the Federal Court of Appeal which had upheld an order

Privacy & cybersecurity update, issue 3 - October, 2014

  • Jones Day
  • -
  • Australia, Brazil, Canada, Chile, China, European Union, France, Germany, Hong Kong, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Russia, Taiwan, USA
  • -
  • October 15 2014

On August 1, the Federal Trade Commission ("FTC") issued a report on mobile shopping applications. In it, the FTC found that such apps often fail to

Plaintiff’s right to videorecord independent medical examinations andor to have a nominee present

  • Field Law
  • -
  • Canada
  • -
  • February 21 2013

The plaintiff sued for personal injury as a result of a motor vehicle accident that occurred on 14 November, 2007. The plaintiff alleged injuries to

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Re-litigation by a patentee with a different party has the federal court been consistent in its approach?

  • SIM. IP Practice
  • -
  • Canada
  • -
  • November 26 2014

Over the past few years the pharmaceutical marketplace has seen an increase in patent "re-litigation" (where a patentee is involved in a second case

Listing patents against combination drugs in Canada ? Changes coming

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in

Federal Court of Appeal holds that prior disclosure of racemate does not anticipate subsequent claim to enantiomer cipralex (escitalopram)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • November 30 2010

On November 25, 2010, the Federal Court of Appeal dismissed three related appeals by Apotex Inc. ("Apotex"), Mylan Pharmaceuticals ULC ("Mylan") and Cobalt Pharmaceuticals Inc. ("Cobalt") (collectively "Generics") to set aside prohibition orders that had been issued by the Federal Court in respect of Canadian Patent No. 1,339,452 ("the '452 Patent") and the medicine escitalopram

Pittman v. Saskatchewan Registered Nurses' Assn. (Discipline Committee)

  • Harper Grey LLP
  • -
  • Canada
  • -
  • May 29 2013

The appellant sought to have a decision of the Saskatchewan Registered Nurses' Association reversed on the basis that its failure to grant the

Sandoz Canada v. Abbott

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 5 2010

This is an appeal and cross-appeal from a decision of the Federal Court in a proceeding commenced pursuant to the Patented Medicines (Notice of Compliance) Regulations